Susquehanna International Group
RCKT icon

Susquehanna International Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Susquehanna International Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$372K Buy
+104,000
New +$413K ﹤0.01% 10385
2025
Q4 		– Sell
-242,700
Closed -$791K – 13387
2025
Q3 		$791K Sell
242,700
-32,500
-12% -$102K ﹤0.01% 7889
2025
Q2 		$674K Buy
275,200
+85,300
+45% +$432K ﹤0.01% 8469
2025
Q1 		$1.27M Buy
+189,900
New +$1.88M ﹤0.01% 6663
2024
Q3 		– Sell
-13,800
Closed -$297K – 12848
2024
Q2 		$297K Sell
13,800
-60,600
-81% -$1.39M ﹤0.01% 9469
2024
Q1 		$2M Sell
74,400
-4,000
-5% -$114K ﹤0.01% 5338
2023
Q4 		$2.35M Buy
78,400
+53,200
+211% +$1.17M ﹤0.01% 5030
2023
Q3 		$516K Buy
25,200
+400
+2% +$7.27K ﹤0.01% 8154
2023
Q2 		$493K Buy
24,800
+6,100
+33% +$123K ﹤0.01% 8354
2023
Q1 		$320K Sell
18,700
-18,300
-49% -$358K ﹤0.01% 9570
2022
Q4 		$724K Sell
37,000
-135,400
-79% -$2.49M ﹤0.01% 6939
2022
Q3 		$2.75M Buy
172,400
+162,000
+1,558% +$2.53M ﹤0.01% 4254
2022
Q2 		$143K Buy
+10,400
New +$124K ﹤0.01% 11087
2021
Q4 		– Sell
-19,200
Closed -$574K – 13760
2021
Q3 		$574K Buy
19,200
+2,300
+14% +$83.7K ﹤0.01% 9024
2021
Q2 		$749K Sell
16,900
-32,000
-65% -$1.39M ﹤0.01% 8560
2021
Q1 		$2.17M Sell
48,900
-45,900
-48% -$2.52M ﹤0.01% 5724
2020
Q4 		$5.2M Buy
94,800
+83,600
+746% +$3.05M ﹤0.01% 3362
2020
Q3 		$256K Sell
11,200
-19,200
-63% -$473K ﹤0.01% 9021
2020
Q2 		$636K Buy
30,400
+18,300
+151% +$330K ﹤0.01% 6852
2020
Q1 		$169K Buy
12,100
+300
+3% +$5.94K ﹤0.01% 8880
2019
Q4 		$269K Sell
11,800
-4,200
-26% -$70.1K ﹤0.01% 8226
2019
Q3 		$186K Buy
16,000
+5,900
+58% +$73.2K ﹤0.01% 9165
2019
Q2 		$152K Sell
10,100
-2,300
-19% -$40.1K ﹤0.01% 9362
2019
Q1 		$217K Buy
+12,400
New +$196K ﹤0.01% 7764
2018
Q4 		– Sell
-9,400
Closed -$231K – 9786
2018
Q3 		$231K Sell
9,400
-1,800
-16% -$39K ﹤0.01% 7964
2018
Q2 		$220K Sell
11,200
-29,900
-73% -$566K ﹤0.01% 8444
2018
Q1 		$771K Buy
41,100
+35,225
+600% +$574K ﹤0.01% 5767
2017
Q4 		$61K Buy
+5,875
New +$58.3K ﹤0.01% 8855
2017
Q1 		– Sell
-17,975
Closed -$439K – 9767
2016
Q4 		$439K Buy
+17,975
New +$513K ﹤0.01% 7261

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's RCKT Position: Q1 2026 in Review

Susquehanna International Group increased its Rocket Pharmaceuticals (RCKT) stake by 99% in Q1 2026, buying an estimated $764K and bringing the position to 385,639 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #7094.

Susquehanna International Group first reported a position in RCKT in Q4 2015 and has held it in 31 quarters since. The position peaked at $7.1M in Q1 2021. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Susquehanna International Group held 385,639 shares of Rocket Pharmaceuticals worth $1.38M as of Q1 2026.
  • Susquehanna International Group bought 192,209 Rocket Pharmaceuticals shares in Q1 2026, an estimated $764K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7094 holding.
  • Susquehanna International Group first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 31 quarters since.
  • Susquehanna International Group's Rocket Pharmaceuticals position peaked at $7.1M in Q1 2021.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.